Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Industriels
  2. Médicament
  3. CINQAERO (reslizumab)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

CINQAERO (reslizumab)

Medicine - Posted on Sep 18 2024
Active substance (DCI)
  • reslizumab
history (3)
  • 7/17/24

    CINQAERO (reslizumab) - Biothérapies par voie sous cutanée dans les maladies inflammatoires chroniques

    Modification des conditions de l'inscription. L'essentiel Avis favorable à la modification des Conditions de Prescription et...
    CAV :
    54321
    icône flèche
  • 10/25/17

    CINQAERO (reslizumab)

    Mise à disposition d’une présentation en flacon de 2,5 ml en complément du flacon de 10 ml. ...
    CAV :
    54321
    icône flèche
  • 7/19/17

    CINQAERO (reslizumab)

    CINQAERO (reslizumab)
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • R03DX08
Manufacturer
TEVA SANTE
Presentation

CINQAERO 10 mg/mL, solution à diluer pour perfusion (code CIS : 68986222)
1 flacon(s) en verre de 10 ml (CIP : 34009 300 673 8 3)
1 flacon(s) en verre de 2,5 ml (CIP : 34009 300 961 2 3)

All our publications
    Bronchial diseases Drug therapy Pain - Inflammation Pulmonary and pleural diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
bjM0qrpPdUfgJEG8